NanoFUSE Biologics Appoints Vice President of Product Business Development

NanoFUSE Biologics has announced the addition of executive Archie Yamada to the team, a trained sales and marketing professional with more than 19 years in the medical device industry with a focus on orthobiologics, orthopedic trauma/joints, and neurosurgical and craniomaxillofacial implants. He joins the NanoFUSE team as vice president of Product Business Development.
 
“Throughout my career, I’ve been heavily involved in the development and sales of orthopedic implants. While I enjoyed providing hardware implants to surgeons, what really motivates me is providing biologic solutions to meet patient needs,” said Yamada.
 
Yamada graduated with an MBA and honors in operations management from the University of Colorado, and a bachelor of arts degree in economics from Brigham Young University. He previously held positions as the clinical sales director for Biologics & Cellular Technology at OsteoMed, regional sales manager for Western U.S. and Canada at Skeletal Kinetics, consultant and regional distributor for DePuy Synthes, as well as Asia Pacific and U.S./EU sales manager for Japan Medical Dynamic Marketing and Ortho Development, respectively.
 
“With NanoFUSE, I was offered the opportunity to collaborate with a team dedicated to supplying cutting edge osteopromotive synthetics. Although this itself is interesting, upon learning NanoFUSE’s direction of not only staying at the forefront of cellular technology, but advancing and defining the biologics of tomorrow, I was ‘all in,’” said Yamada.
 
The NanoFUSE Biologics platform has the only U.S. Food and Drug Administration-cleared combination of demineralized bone matrix (DBM) and synthetic bioactive glass technology, providing both osteoinductive and osteoconductive properties. The NanoFUSE DBM putty has been used successfully in more than 1,000 cases by over 200 surgeons in various orthopedic applications.
 
“The NanoFUSE acquisition was a strategic addition to our orthopedic and spine portfolio to provide surgeons a comprehensive product offering. Archie’s leadership is timely as we focus on accelerating revenues and establishing distribution in the U.S. and overseas. We expect strong market demand to continue with attractive returns for our investors, and are encouraged by the recent partnership by DePuy Synthes for Prosidyan’s FIBERGRAFT synthetic product,” said KICVentures Managing Partner and Chief Financial Officer Aditya Humad. NanoFUSE Biologics LLC is a KICVentures portfolio company.
 
The NanoFUSE Bioactive Matrix is a unique and proprietary blend of demineralized bone matrix (DBM) that combines the osteoinductive capabilities of DBM with the osteostimulative properties of bioactive glass. NanoFUSE Biologics LLC is a KICVentures portfolio company, distributed by SpineFrontier.